JRS Chemistry’s Post

Mary McCarthy, Partner in our Industrial Biotech strategy, moderated a panel at the Rethinking Materials Summit with esteemed industry peers Niels Van Stralen, Nethaji Gallage Jason Robinson, Gudrun Vogtentanz and Dr Jen Vanderhoven. They delved into the fascinating world of advancing the bioeconomy, specifically focusing on "Plant-Based Specialty Chemicals and Bio-Based Building Block Molecules." Key points from their discussion: - The importance of keeping a balance between functionality and cost for a receptive market reaction - The challenges that come with scaling including the importance of collaboration, partnering across the supply chain and need for a supportive network and empowering associations - Fundraising tips: start early, but don’t start too early, choose investors who will bring more than money, choose those who will bring network and be able to strengthen your board and help your company grow - The role policy plays in building the foundation of the bioeconomy We look forward to continuing these conversations throughout the year, exploring new ideas, and collaborating with like-minded individuals and organizations. ChainCraft Evoco Ltd. AMSilk GmbH | Biotech Materials Octarine Bio BBIA #Bioeconomy #Sustainability #IndustrialBiotech #Innovation

Biotech Challenge – Your Thoughts! 🌍🔬  If you could solve ONE major global challenge using biotechnology, what would it be? From eradicating diseases to reducing plastic waste, the possibilities are endless! Comment below with your idea and join the conversation! Let's dream big together! 💡

Company values should be authentic, but not over-reaching – they must be rooted in reality. And they also must keep changing and evolving. You may have had the most incredible success with your company values to date, but as Marshall Goldsmith famously said: “what got you here won’t get you there”. Look ahead; making the necessary changes to your values and culture will set you in good stead to mature and grow as a company. Most importantly – take action early. #growth #values #companyculture #biotech #biotechnology

𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝗶𝗻 𝗧𝗵𝗶𝘀 𝗠𝗼𝗿𝗻𝗶𝗻𝗴’𝘀 𝗟𝗦𝗘 𝗨𝗽𝗱𝗮𝘁𝗲 We are pleased to announce the successful completion of a £500,000 fundraising, demonstrating strong investor confidence in our vision and capabilities. These funds will accelerate progress across our subsidiaries, driving advancements in lab-grown leather, cultivated meat, regenerative medicine through our corneal technology, and the launch of CytoBoost™—a next-generation cell culture additive addressing diverse markets. This strategic investment strengthens our ability to achieve key milestones and deliver innovative biotechnological solutions that meet growing market demand, while supporting a more sustainable future. Read the full announcement here: https://lnkd.in/g45Q2YUE #BSFA #BSFAF #LabGrownMeat #CultivatedMeat #LabGrownLeather #Biotech #SustainableBiotech #CornealTreatment #HealthCareInnovation #BSFEnterprise #3DBT #KeratoLtd #Biotechnology @BSF_Enterprise @3D_BioTissues

We are excited to announce the first close of Forbion BioEconomy Fund I at €75 million. This new fund, led by Alexander Hoffmann and Joy Faucher, focuses on biotech-enabled solutions in #Food, #Agriculture, #Materials, and #Environmental #Technologies. The Forbion BioEconomy Fund aims to transform industries reliant on non-renewable resources by investing in sustainable, scalable, and cost-effective alternatives. Our team is supported by industry veterans Feike Sijbesma, ex-CEO of DSM, Cees de Jong, Chairman of Novonesis, Onno van de Stolpe, ex-CEO of Galapagos, and Stefan Oschmann, ex-CEO of Merck KGaA as Advisors and Venture Partners. This fund is a strategic expansion, leveraging our biotech expertise to address pressing planetary challenges. Join us as we drive innovations that will help clean and feed the planet. Click on the following link to learn more: https://lnkd.in/eumrYSSF #VentureCapital #Biotech #Sustainability #Forbion #BioEconomy

Solugen's announcement of their conditional loan from the DOE is one of the most encouraging pieces of synbio news I've heard in a while. I don't know the full details, but this type of financing indicates they sufficiently proved the repeatability/scalability of their forges. For an industry that's been plagued with issues involving scale-up, this is a pretty big deal. Congrats Gaurab and Sean! If you want to learn more about Solugen's story, you can check out my piece on them from last year: https://lnkd.in/ghaQqr87 It's interesting to note that one of the synbio companies most aggressively scaling is based on cell-free technology. Niko McCarty and I covered this in our piece on alternatives to fermentation-based bioproduction: https://lnkd.in/g_7-eW3G Finally, I think this is a really interesting example of financing the development of new facilities with non-equity instruments once the TEA and feasibility at scale have been validated. More on this concept here: https://lnkd.in/gib4TTMc

Your science can be incredible. You might have raised more money than you dreamed of. But neglect your People & Culture pillar at your peril... Come watch the rest of the video now at https://lnkd.in/e5fF5UM3 #people #culture #biotech #biotechnology #drugdiscovery #drugdevelopment

The final results of our #BIO2024 step competition are in. Technically, there is one more day of BIO, but we limited the competition to the three "heavy days". Jessica Davis wins bragging rights with over 50K steps (~21 miles) walked and sometimes ran during the show. Her victory embodies one of the pillars of Dynamk Capital's investment strategy - CONSISTENCY! A key message we heard this week at BIO was that companies are indeed seeing positive growth indicators. Those who circled the wagons the past 12-18 months and focused on their core business, like Dyanmk Capital's portfolio companies, are poised to capitalize in 2024. A special thanks to our partners who co-exhibited this year at BIO: CellFE RoosterBio Inc. Vernal Biosciences Virica Biotech #venturecapital #biomanufacturing #drugdiscovery #cellandgenemanufacturing

10 days until BIONATION 2024! Up next in our BIONATION Builder spotlight is, Fonds de solidarité FTQ. The Fonds de solidarité FTQ is a source of pride in Québec, fulfilling its mission through a unique business model created more than 40 years ago. Since then, the Fonds has rallied Québec into action thanks to the retirement savings of over 785,000 shareholders. With net assets of $20 billion as at May 31, 2024, the Fonds supports thousands of companies through venture- and development-capital investments based on the belief that impact is created as much by financial as societal returns. For more information, visit www.fondsftq.com or its company page on LinkedIn. For more information about BIONATION visit: biotech.ca/BIONATION Looking forward to the Fonds' valuable contribution at BIONATION as we work together to shape the future of Canadian biotechnology. #biotechnology #ecosystem #biotech #canada #innovation #publicpolicy #cdnpoli #bionation2024 #BIONATIONBuilder #BIONATION #BIONATION2024

Rewards and recognition don’t just have to mean yearly bonuses. There are plenty of different ways you can go about letting your team know their work is appreciated. I’ll be dropping some more tips and advice about rewards and recognition throughout the week, so keep an eye out! #rewards #recognition #ceo #development #biotech #biotechnology